BloodPressureHeartMeds.Org

Celtic Pharma receives US patent for methods to treat breast, colon cancer

October 05, 2017

Preclinical Studies

Several preclinical studies using implanted solid tumor (breast and colon) human xenografts into nude mice, as well as both pediatric and adult human brain tumor xenografts, were evaluated when treated with Xerecept? alone and in combination with Avastin?.  All of these particular models demonstrated statistically significant tumor regression and prolongation of survival following combination treatment with Xerecept and Avastin, compared to Xerecept or Avastin alone.

Specifically, in the human breast model, both Xerecept and Avastin by themselves produced similar antitumor effects; however, when Xerecept was combined with Avastin, the antitumor effect was significantly increased (p<0.001). The enhanced combination effect was statistically different (p<0.03) than either result associated with the monotherapies.  In the human colon xenograft model, Xerecept was not active alone against this tumor model while Avastin produced a significant tumor growth delay compared to the vehicle-treated control.  However, the combination therapy of Xerecept plus Avastin significantly increased the overall survival of animals when compared to treatment with vehicle (p<0.001) or Avastin alone (p<0.01).  In the high grade pediatric glioblastoma model, Xerecept demonstrated activity by itself and the combination of Xerecept with Avastin was significantly better than Xerecept or Avastin alone.  These preclinical findings demonstrate that Xerecept has the ability to potentiate or provide a synergistic enhancement of the antitumor effects of Avastin in these various models.

SOURCE Celtic Pharmaceutical Holdings L.P.